Why is Sutro Biopharma Stock Falling On Wednesday?
Sutro Biopharma stock falls after its STRO-004 Phase 1 update, with DLTs reported at the highest dose and the next update planned for 2027.
Sutro Biopharma reported safety problems with their medicine at the highest test dose, which made investors worried. Watch how the company fixes this issue over the next few years, since their next big update won't come until 2027.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.